Recommended for general use within NHS in Scotland.
FemSeven Sequi offers an alternative sequential combined hormone replacement therapy (HRT) for the treatment of oestrogen deficiency symptoms in postmenopausal women. It is formulated as a transdermal patch and is the first sequential combined HRT patch to allow once weekly application. It is not licensed for the prophylaxis of osteoporosis.
Download detailed advice16KB (PDF)
- Medicine name:
- Estradiol & levonorgesteral patches (FemSeven Sequi®)
- SMC ID:
- Hormone replacement therapy for oestrogen deficiency symptoms in post-menopausal women
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Endocrine system
- Submission type
- Date advice published
- 06 December 2002